β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways

Giovanni Fajardo1, Mingming Zhao, Gerald Berry

  • 1Department of Pediatrics (Cardiology), Stanford University, Stanford, CA, USA.

Insights

Beta-2 adrenergic receptors (β2-ARs) protect the heart from doxorubicin-induced cardiotoxicity by activating pro-survival pathways and maintaining mitochondrial function. Their absence exacerbates toxicity through impaired signaling and increased calcium, leading to mitochondrial dysfunction.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Beta-adrenergic receptors (β-ARs) play a role in cardiac function and response to stress.
  • Doxorubicin (DOX) cardiotoxicity involves mitochondrial permeability transition (MPT) and calcium dysregulation.
  • The precise signaling pathways linking β2-ARs to mitochondrial regulation in DOX cardiotoxicity remain unclear.

Purpose of the Study:

  • To investigate the mechanisms of crosstalk between β2-ARs and mitochondrial cell death pathways during DOX-induced cardiotoxicity.
  • To elucidate the role of β2-ARs in regulating pro-survival kinases and mitochondrial function under oxidative stress.

Main Methods:

  • Comparison of doxorubicin (DOX) effects on wild-type (WT) and β2-AR knockout (β2-/-) mice.
  • Assessment of pro-survival kinase activity (εPKC, Akt) and response to pharmacological modulators (ψεRACK, prazosin).
  • Measurement of intracellular calcium ([Ca2+]i) in cardiomyocytes and mitochondrial function (Complex I/II activity, MPT) with and without β2-ARs, using verapamil and cyclosporine as blockers.

Main Results:

  • Absence of β2-ARs significantly increased mortality following DOX exposure.
  • DOX induced decreased activity of pro-survival kinases (εPKC, Akt) in β2-/- mice, which was partially restored by ψεRACK and prazosin, respectively.
  • β2-AR deletion enhanced cardiomyocyte calcium release and disrupted mitochondrial architecture and function, with MPT blockers reducing mortality.

Conclusions:

  • β2-ARs are crucial for cardioprotection against DOX-induced cardiotoxicity by activating pro-survival kinases and preserving mitochondrial integrity.
  • The absence of β2-ARs leads to enhanced cardiotoxicity through impaired survival signaling and increased intracellular calcium, predisposing mitochondria to MPT.
  • Targeting β2-ARs or downstream pathways may offer therapeutic strategies against DOX cardiotoxicity.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...